GO:1900753 doxorubicin transport: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900753 (doxorubicin transport) describes the directed movement of doxorubicin into, out of, or within a cell, or between cells, by means of a transporter or pore.
• Doxorubicin transport is mediated by multiple systems, including ATP-dependent pumps such as RLIP76 and P-glycoprotein, as well as secondary multidrug transporters like NorM.
• Bacterial multidrug transporters such as NorM from Vibrio cholerae provide structurally tractable models for studying doxorubicin recognition and transport.
• Altered doxorubicin transport is a central mechanism of anthracycline resistance in cancer cells and influences cardiotoxicity.
• Methylxanthine derivatives can modulate doxorubicin transport and antitumor activity, highlighting transport as a druggable node.
• Doxorubicin transport can be measured biochemically using purified proteins and membrane-based assays, enabling mechanistic and pharmacological studies.
Description
Doxorubicin (Adriamycin) is an anthracycline chemotherapeutic whose cellular distribution and efficacy depend on active transport processes. GO:1900753, doxorubicin transport, is defined as the directed movement of doxorubicin into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This process is fundamental to drug pharmacokinetics, resistance, and toxicity, and it is mediated by a diverse set of membrane proteins ranging from ATP-binding cassette (ABC) transporters to secondary multidrug transporters. Understanding doxorubicin transport is therefore critical for interpreting drug response and for designing strategies to overcome resistance or reduce off-target damage. Research on doxorubicin transport spans bacterial and human systems. Bacterial multidrug transporters such as NorM from Vibrio cholerae have been used to dissect the molecular basis of doxorubicin recognition and transport, providing high-resolution mechanistic insights. In human cells, ATP-dependent transport of doxorubicin has been attributed to RLIP76 and to mechanisms distinct from P-glycoprotein, underscoring the multiplicity of transport routes. These findings have direct implications for anthracycline-induced cardiotoxicity and for the development of transport-modulating agents. This article synthesizes the authoritative GO definition and verified literature to outline the mechanisms, key genes, disease links, and experimental methods relevant to GO:1900753. It is intended for researchers seeking a concise, citation-backed overview of doxorubicin transport as a biological process.
doxorubicin transport At A Glance
| GO ID | GO:1900753 |
|---|---|
| GO term | doxorubicin transport |
| Ontology | biological_process |
| Synonym | Adriamycin transport; 14-hydroxydaunomycin transport; doxorubicine transport; doxorubicinum transport |
| Definition | The directed movement of a doxorubicin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Mediates cellular and transcellular distribution of doxorubicin, influencing drug efficacy, resistance, and toxicity. |
| Key transport systems | ATP-dependent transporters (e.g., RLIP76, P-glycoprotein) and secondary multidrug transporters (e.g., NorM). |
| Disease relevance | Anthracycline resistance in cancer and anthracycline-induced cardiotoxicity. |
What Is GO:1900753?
GO:1900753 (doxorubicin transport) is the biological process by which doxorubicin, also known as Adriamycin or 14-hydroxydaunomycin, is moved into, out of, or within a cell, or between cells, through the action of a transporter or pore. This definition encompasses both influx and efflux events and does not specify a particular molecular mechanism, allowing for ATP-dependent pumps, secondary active transporters, and other transport systems to be included.
Why Is doxorubicin transport Important in Cell Biology?
Doxorubicin transport is a determinant of chemotherapeutic response and toxicity. Because doxorubicin must reach intracellular targets such as topoisomerase II and DNA to exert its cytotoxic effects, the efficiency of its transport directly modulates antitumor activity. Conversely, enhanced efflux or altered intracellular trafficking can confer resistance, a major clinical challenge. In addition, transport processes influence doxorubicin accumulation in non-target tissues such as the heart, contributing to cardiotoxicity. Understanding the molecular players and regulatory mechanisms of doxorubicin transport is therefore essential for optimizing anthracycline therapy and for developing transport-targeted interventions.
• Doxorubicin transport determines intracellular drug concentrations and thus antitumor efficacy.
• Altered transport is a mechanism of acquired resistance to anthracyclines in cancer cells.
• Transport systems such as RLIP76 and P-glycoprotein contribute to doxorubicin efflux and resistance.
• Bacterial multidrug transporters like NorM provide mechanistic models for doxorubicin recognition and transport.
• Doxorubicin transport influences drug distribution to the heart and may contribute to cardiotoxicity.
• Modulation of transport by methylxanthine derivatives can alter antitumor activity, indicating pharmacological tractability.
• Doxorubicin transport assays are used to characterize transporter specificity and inhibitor sensitivity.
• Understanding transport mechanisms supports the rational design of P-glycoprotein inhibitors and other transport modulators.
• Transport studies bridge cancer pharmacology, microbiology, and structural biology.
What Happens During doxorubicin transport?
Substrate recognition and binding
In simple terms: The transporter first recognizes and binds doxorubicin.
Doxorubicin transport begins with the recognition of the drug by a membrane-embedded transporter. Structural and biochemical studies of the MATE multidrug transporter NorM from Vibrio cholerae have revealed how doxorubicin is recognized and bound, providing a framework for understanding substrate specificity in this process. In human systems, ATP-dependent transporters such as RLIP76 also bind doxorubicin and glutathione conjugates, indicating that substrate recognition can involve multiple chemical determinants.
Translocation across the membrane
In simple terms: The transporter moves doxorubicin across the cell membrane.
Following binding, the transporter undergoes conformational changes that translocate doxorubicin across the lipid bilayer. For NorM, this step is coupled to the electrochemical gradient, whereas RLIP76-mediated transport is ATP-dependent. ATP-dependent transport of doxorubicin, daunomycin, and vinblastine has been demonstrated in human tissues by a mechanism distinct from P-glycoprotein, highlighting the diversity of translocation mechanisms.
Energy coupling and driving forces
In simple terms: Different transporters use different energy sources to move doxorubicin.
Doxorubicin transport can be energized by ATP hydrolysis or by ion gradients. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. In contrast, secondary multidrug transporters such as NorM utilize the sodium or proton motive force. This energetic diversity means that transport activity can be modulated by cellular metabolic state and by inhibitors targeting specific coupling mechanisms.
Efflux and cellular distribution
In simple terms: Once inside, doxorubicin can be pumped out or redistributed within the cell.
Efflux of doxorubicin from cells is a key determinant of drug resistance. Studies of Adriamycin resistance in vivo have linked glutathione metabolism, P-glycoprotein expression, and drug transport to reduced intracellular drug accumulation. In addition, doxorubicin transport can affect organellar distribution; for example, doxorubicin alters pyruvate transport in rat-heart mitochondria, suggesting effects on mitochondrial function.
Modulation by pharmacological agents
In simple terms: Certain drugs can change how doxorubicin is transported.
Methylxanthine derivatives have been shown to affect doxorubicin transport and antitumor activity, indicating that transport can be pharmacologically modulated. Such modulation may be exploited to enhance drug retention in tumor cells or to reduce toxicity in sensitive tissues.
Key Genes Involved in GO:1900753 doxorubicin transport
The following genes and proteins have been experimentally implicated in doxorubicin transport or in related transport processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RLIP76 (RALBP1) | ATP-dependent transporter of glutathione-conjugates and doxorubicin | Major efflux pump in human erythrocytes; target for resistance studies |
| ABCB1 (P-glycoprotein) | ATP-dependent efflux transporter | Classic multidrug resistance mediator; linked to doxorubicin resistance |
| NorM (Vibrio cholerae) | Secondary multidrug transporter (MATE family) | Structural model for doxorubicin recognition and transport |
| MATE family transporters | Ion-coupled multidrug efflux | Bacterial and eukaryotic homologs studied for doxorubicin transport |
| Glutathione S-transferases | Conjugation and transport-related detoxification | Associated with Adriamycin resistance and glutathione metabolism |
| Mitochondrial pyruvate carrier | Mitochondrial pyruvate transport | Affected by doxorubicin, linking transport to mitochondrial toxicity |
| ABC transporters (other) | ATP-dependent efflux | Potential contributors to doxorubicin transport distinct from P-glycoprotein |
| SLC transporters | Solute carrier-mediated transport | Candidate influx/efflux routes for anthracyclines |
| Topoisomerase II (target) | Not a transporter; drug target | Intracellular target whose access depends on transport |
| Glutathione (GSH) system | Redox and conjugate transport | Modulates doxorubicin transport and resistance |
| RLIP76 (alternative name) | ATP-dependent transport | Studied in erythrocytes and cancer cells |
| P-glycoprotein (ABCB1) | Efflux pump | Expression correlates with drug transport in resistant models |
| NorM homologs | MATE transporters | Used to dissect substrate binding and conformational cycling |
| Methylxanthine targets | Modulators of transport | Pharmacological tools to alter doxorubicin transport |
| Anthracycline transport proteins | Various | General category for transporters studied in cardiotoxicity |
How Is doxorubicin transport Regulated?
Doxorubicin transport is regulated at multiple levels. Expression of ATP-dependent transporters such as RLIP76 and P-glycoprotein can be modulated by cellular stress and drug exposure, contributing to acquired resistance. Glutathione metabolism influences transport activity, as glutathione conjugates are co-transported by RLIP76. In addition, pharmacological agents such as methylxanthine derivatives can acutely regulate transport and antitumor activity. The activity of secondary transporters like NorM depends on ion gradients, which are in turn regulated by cellular energetics. These layers of regulation make doxorubicin transport a dynamic and context-dependent process.
doxorubicin transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 (P-glycoprotein) | Multidrug resistance in cancer | ABCB1 knockout cancer cell lines; doxorubicin efflux assays |
| RLIP76 (RALBP1) | Doxorubicin resistance | RLIP76 knockdown or knockout cells; transport assays |
| NorM (Vibrio cholerae) | Bacterial multidrug resistance | NorM mutants in E. coli; doxorubicin transport measurements |
| SLC transporters | Anthracycline cardiotoxicity | Cardiomyocyte models with transporter knockout |
| Mitochondrial pyruvate carrier | Mitochondrial dysfunction | Isolated mitochondria from doxorubicin-treated hearts |
Cancer drug resistance
Enhanced doxorubicin efflux is a well-documented mechanism of anthracycline resistance. Studies in resistant tumor models have linked increased drug transport to glutathione metabolism and P-glycoprotein expression, resulting in reduced intracellular drug accumulation and diminished cytotoxicity. ATP-dependent transporters such as RLIP76 also contribute to doxorubicin efflux in human cells, providing additional routes for resistance. Targeting these transport pathways is a potential strategy to restore drug sensitivity.
Anthracycline-induced cardiotoxicity
Doxorubicin transport influences drug distribution to the heart, where accumulation can cause cardiotoxicity. Drug transporters, including ABC and SLC family members, have been implicated in anthracycline-induced cardiotoxicity, and genetic variation in these transporters may modulate individual risk. Understanding transport mechanisms in cardiomyocytes could inform cardioprotective strategies.
Mitochondrial dysfunction
Doxorubicin affects mitochondrial transport processes; for example, it alters pyruvate transport in rat-heart mitochondria, which may contribute to mitochondrial dysfunction and cardiotoxicity. This highlights a link between doxorubicin transport and organellar metabolism.
From doxorubicin transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RLIP76 reduce doxorubicin efflux? | RLIP76 knockout cell line |
| Does ABCB1 point mutation alter substrate specificity? | ABCB1 point-mutant knock-in cells |
| Can a tagged transporter be used to track localization? | Tagged knock-in of MATE transporter |
| Does overexpression of a candidate transporter confer resistance? | Overexpression cell model |
| Does a bacterial transporter recognize doxorubicin? | NorM knockout and complementation in bacteria |
| Does transporter genotype affect cardiotoxicity? | Patient-derived cardiomyocytes or animal models |
How to Study the doxorubicin transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Proteoliposome transport assay | Direct transport of doxorubicin by purified protein | Mechanistic studies of NorM and other transporters |
| Fluorescence-based efflux assay | Intracellular doxorubicin retention | Cancer cell resistance profiling |
| ATPase activity assay | ATP hydrolysis coupled to transport | Characterization of ATP-dependent transporters |
| Glutathione-conjugate transport assay | Co-transport of glutathione conjugates | RLIP76 functional studies |
| Mitochondrial substrate uptake | Transport of pyruvate and other substrates | Doxorubicin mitochondrial toxicity |
| Gene expression analysis | Transporter mRNA/protein levels | Correlation with resistance phenotype |
| Pharmacological modulation assay | Effect of inhibitors on transport | Screening for transport modulators |
Transport assays with purified proteins
Doxorubicin transport can be measured using purified bacterial multidrug transport proteins reconstituted into proteoliposomes or membrane vesicles. These assays allow direct quantification of transport activity and substrate specificity. Such methods have been applied to NorM from Vibrio cholerae to dissect doxorubicin recognition.
Cell-based efflux and accumulation assays
Cellular doxorubicin transport is commonly assessed by measuring intracellular drug accumulation or efflux using fluorescence-based or radiolabeled assays. These approaches have been used to study ATP-dependent transport in human erythrocytes and resistant cancer cells.
Biochemical characterization of ATP-dependent transporters
ATPase activity and glutathione-conjugate transport assays can identify ATP-dependent doxorubicin transporters such as RLIP76. Such biochemical methods distinguish transport mechanisms from P-glycoprotein-mediated efflux.
Mitochondrial transport measurements
Doxorubicin effects on mitochondrial transport can be studied using isolated mitochondria and specific substrate uptake assays, as shown for pyruvate transport in rat-heart mitochondria.
How CRISPR Can Be Used to Study GO:1900753 doxorubicin transport
Knockout
CRISPR knockout of candidate transporter genes such as RLIP76 or ABCB1 can be used to determine their contribution to doxorubicin transport. Loss-of-function models enable direct measurement of drug accumulation and resistance phenotypes.
Point Mutation
Point mutations in transporter genes can be introduced to test the role of specific residues in doxorubicin recognition and translocation. Such models are valuable for dissecting substrate-binding pockets identified in structural studies.
Knock-in
Knock-in of tagged or reporter versions of transporters allows real-time tracking of protein localization and dynamics during doxorubicin transport. This approach can be applied to both human and bacterial transporters.
Overexpression
Overexpression of candidate transporters in naive cells can confer doxorubicin resistance, providing functional evidence for their role in transport. This strategy has been used to study P-glycoprotein and other efflux pumps.
How EDITGENE Supports doxorubicin transport Research
Researchers studying doxorubicin transport-related genes often need to determine whether a candidate gene is causally involved in drug movement, resistance, or toxicity. CRISPR-based models provide a direct way to test these hypotheses by manipulating transporter genes in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for doxorubicin transport research.
Frequently Asked Questions About doxorubicin transport
What is doxorubicin transport?
Doxorubicin transport is the directed movement of doxorubicin into, out of, or within a cell, or between cells, by means of a transporter or pore, as defined by GO:1900753.
What genes are involved in doxorubicin transport?
Genes and proteins implicated in doxorubicin transport include RLIP76 (RALBP1), ABCB1 (P-glycoprotein), and bacterial multidrug transporters such as NorM.
How is doxorubicin transported out of cells?
Doxorubicin can be effluxed by ATP-dependent transporters such as RLIP76 and P-glycoprotein, as well as by secondary multidrug transporters.
Why is doxorubicin transport important in cancer?
Transport determines intracellular drug levels and is a key mechanism of anthracycline resistance and toxicity.
What is the role of P-glycoprotein in doxorubicin transport?
P-glycoprotein is an ATP-dependent efflux pump that contributes to doxorubicin resistance, although other transporters also play a role.
Can doxorubicin transport be measured experimentally?
Yes, transport can be measured using purified protein assays, cell-based efflux assays, and mitochondrial uptake studies.
What is NorM and how does it transport doxorubicin?
NorM is a MATE family multidrug transporter from Vibrio cholerae that recognizes and transports doxorubicin using an ion gradient.
Does doxorubicin affect mitochondrial transport?
Doxorubicin has been shown to alter pyruvate transport in rat-heart mitochondria, linking it to mitochondrial dysfunction.
Can drugs modulate doxorubicin transport?
Methylxanthine derivatives can affect doxorubicin transport and antitumor activity, indicating pharmacological modulation is possible.
How can CRISPR help study doxorubicin transport?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional testing of candidate transporters in doxorubicin transport and resistance.
Conclusion
GO:1900753 (doxorubicin transport) is a biologically and clinically significant process that governs the cellular distribution of a widely used chemotherapeutic. It is mediated by diverse transporters, including ATP-dependent pumps such as RLIP76 and P-glycoprotein, and secondary multidrug transporters such as NorM. Dysregulation of doxorubicin transport contributes to drug resistance and cardiotoxicity, making it a target for pharmacological intervention. Continued research using biochemical, cellular, and CRISPR-based models will refine our understanding of this process and support the development of improved anthracycline therapies.
References
- 1. Hsieh PY et al.. 2025. Doxorubicin transport measurements for a bacterial multidrug transport protein.. Methods Enzymol 724:83-97 PMID: 41309185
- 2. Kakuyama A et al.. 2001. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity.. Curr Drug Metab 2(4):379-95 PMID: 11766989
- 3. Hsieh PY et al.. 2026. Doxorubicin Recognition and Transport by the MATE Multidrug Transporter NorM From Vibrio cholerae.. J Mol Biol 438(2):169549 PMID: 41260293
- 4. Sharma R et al.. 2001. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes.. Arch Biochem Biophys 391(2):171-9 PMID: 11437348
- 5. Awasthi S et al.. 1994. Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.. J Clin Invest 93(3):958-65 PMID: 7907606
- 6. Paradies G et al.. 1988. The effect of doxorubicin on the transport of pyruvate in rat-heart mitochondria.. Biochem Biophys Res Commun 156(3):1302-7 PMID: 3190705
- 7. Lee FY et al.. 1989. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.. Biochem Pharmacol 38(21):3697-705 PMID: 2574574
- 8. Huang KM et al.. 2018. Drug transporters and anthracycline-induced cardiotoxicity.. Pharmacogenomics 19(11):883-888 PMID: 29991332
